article thumbnail

A spatial approach to understanding drug dynamics using mass spectrometry imaging

Drug Target Review

2025 Feb 4 About the authors Steve Castellino – Chief Analytics Officer & Principal Investigator, GlycoPath Steve Castellino received his BA in Chemistry from California State University, Long Beach, and his PhD in Organic Chemistry from the University of California, Riverside. Toxicologic Pathology.

Drugs 52
article thumbnail

Nixing the Newborn Screening Advisory Committee Is Ill-Advised

PLOS: DNA Science

Baby’s First Test categorizes the entries: amino acid, endocrine, fatty acid oxidation, and hemoglobin disorders; lysosomal storage diseases; organic acid conditions; and others. It is jargony enough to reawaken nightmares of taking organic chemistry.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

New chemical process makes it easier to craft amino acids that don't exist in nature

Science Daily: Pharmacology News

Chemists describe a powerful new way to create new-to-nature, 'unnatural' amino acids, which could find use in protein-based therapies and open up novel branches of organic chemistry.

article thumbnail

A demonstration of substituent effects in anti-aromatic compounds

SCIENMAG: Medicine & Health

On the other hand, anti-aromatic compounds with 4n pi-electrons have been conventionally considered unstable, and the creation of stable anti-aromatic compounds has been one of the challenging issues in organic chemistry. Several studies […]

article thumbnail

API Processes in the Pharmaceutical Industry

DS in Pharmatics

I earned a Bachelor of Science in Chemistry at Fairfield University in 1979 and a Ph.D. in Organic Chemistry at Yale University in 1984 […] Could you please introduce yourself and your expertise in the pharmaceutical industry?

article thumbnail

Bavtavirine

New Drug Approvals

Institute of Organic Chemistry and Biochemistry of the AS CR, v.v.i. Bavtavirine, CAS 1956373-71-9 KAJ2CK6ZYE 4-((4-Amino-8-(4-((1E)-2-cyanoethenyl)-2,6-dimethylphenyl)-2-quinazolinyl)amino)benzonitrile Benzonitrile, 4-((4-amino-8-(4-((1E)-2-cyanoethenyl)-2,6-dimethylphenyl)-2-quinazolinyl)amino)- C 26 H 20 N 6 416.48

article thumbnail

FDA Sets a Recommended Framework for Predicting the Mutagenic and Carcinogenic Potential of Nitrosamine Drug Substance-Related Impurities

FDA Law Blog: Biosimilars

This second half of this guidance beginning with the “Flowchart to Predict the Carcinogenic Potency Category of an NDSRI and Identify an Associated Recommended AI Limit” takes one back to basic organic chemistry and breaks down the key structural and electronic considerations into a step-by-step guide.

FDA 74